Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome
Aim. To study clinical, hemodynamic, and metabolic effects of 12-week therapy with Noliprel® (perindopril 2 mg plus indapamide 0.625 mg) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. Twenty-five patients with AH and MS were enrolled in the study. At b...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2005-06-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/968 |
| _version_ | 1827064150399909888 |
|---|---|
| author | O. N. Andreeva I. M. Korochkin N. P. Rechnova V. Yu. Pibovarov |
| author_facet | O. N. Andreeva I. M. Korochkin N. P. Rechnova V. Yu. Pibovarov |
| author_sort | O. N. Andreeva |
| collection | DOAJ |
| description | Aim. To study clinical, hemodynamic, and metabolic effects of 12-week therapy with Noliprel® (perindopril 2 mg plus indapamide 0.625 mg) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. Twenty-five patients with AH and MS were enrolled in the study. At baseline, as well as after 12 weeks of Noliprel® and Noliprel Forte® therapy, 24-hour blood pressure monitoring (BPM), metabolic and hemostatic parameters’ assessments were performed. Results. Twelve-week therapy with Noliprel® and Noliprel Forte® resulted in decrease of circadian BP, day- and night-time pressure load indices, and BP bi-phase profile normalization. Treatment with Noliprel® and Noliprel Forte® did not significantly influence plasma levels of lipids, glucose, or insulin. Initially increased platelet aggregation substantially improved during the treatment. Conclusion. The results obtained demonstrate good antihypertensive effects during the whole day, and metabolic neutrality for both medications. |
| first_indexed | 2024-04-10T03:41:25Z |
| format | Article |
| id | doaj.art-34c19f0527264960b882bb34785aa07c |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2025-03-19T22:42:34Z |
| publishDate | 2005-06-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-34c19f0527264960b882bb34785aa07c2024-10-17T12:21:22Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-06-0143, ч.I4652682Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndromeO. N. Andreeva0I. M. Korochkin1N. P. Rechnova2V. Yu. Pibovarov3Russian State Medical UniversityRussian State Medical UniversityClinical Hospital No. 13, MoscowRussian State Medical UniversityAim. To study clinical, hemodynamic, and metabolic effects of 12-week therapy with Noliprel® (perindopril 2 mg plus indapamide 0.625 mg) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. Twenty-five patients with AH and MS were enrolled in the study. At baseline, as well as after 12 weeks of Noliprel® and Noliprel Forte® therapy, 24-hour blood pressure monitoring (BPM), metabolic and hemostatic parameters’ assessments were performed. Results. Twelve-week therapy with Noliprel® and Noliprel Forte® resulted in decrease of circadian BP, day- and night-time pressure load indices, and BP bi-phase profile normalization. Treatment with Noliprel® and Noliprel Forte® did not significantly influence plasma levels of lipids, glucose, or insulin. Initially increased platelet aggregation substantially improved during the treatment. Conclusion. The results obtained demonstrate good antihypertensive effects during the whole day, and metabolic neutrality for both medications.https://cardiovascular.elpub.ru/jour/article/view/968metabolic syndromecombined low-dose therapyarterial hypertensionplatelet aggregationmetabolic neutrality |
| spellingShingle | O. N. Andreeva I. M. Korochkin N. P. Rechnova V. Yu. Pibovarov Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome Кардиоваскулярная терапия и профилактика metabolic syndrome combined low-dose therapy arterial hypertension platelet aggregation metabolic neutrality |
| title | Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome |
| title_full | Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome |
| title_fullStr | Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome |
| title_full_unstemmed | Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome |
| title_short | Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome |
| title_sort | efficacy safety of combined perindopril and indapamide low dose therapy in patients with arterial hypertension and metabolic syndrome |
| topic | metabolic syndrome combined low-dose therapy arterial hypertension platelet aggregation metabolic neutrality |
| url | https://cardiovascular.elpub.ru/jour/article/view/968 |
| work_keys_str_mv | AT onandreeva efficacysafetyofcombinedperindoprilandindapamidelowdosetherapyinpatientswitharterialhypertensionandmetabolicsyndrome AT imkorochkin efficacysafetyofcombinedperindoprilandindapamidelowdosetherapyinpatientswitharterialhypertensionandmetabolicsyndrome AT nprechnova efficacysafetyofcombinedperindoprilandindapamidelowdosetherapyinpatientswitharterialhypertensionandmetabolicsyndrome AT vyupibovarov efficacysafetyofcombinedperindoprilandindapamidelowdosetherapyinpatientswitharterialhypertensionandmetabolicsyndrome |